IN CERTAIN CANCERS, GIVING CHEMOTHERAPY PREOPERATIVELY MAY RESULT IN A SURVIVAL ADVANTAGE

Posted on by Peter Rigney

IN CERTAIN CANCERS, GIVING CHEMOTHERAPY PREOPERATIVELY MAY RESULT IN A SURVIVAL ADVANTAGE

Key Insights

  • Neoadjuvant therapy was once valued primarily for surgical benefits — shrinking tumors, preserving options such as nipple-sparing mastectomy, and reducing the need for full lymph node dissection.
  • Until recently, survival benefit had not been proven, but new trials now demonstrate measurable improvements in long-term outcomes.
  • KEYNOTE-522 and ISPY2 trials showed that immune checkpoint inhibitors, when added to chemotherapy, significantly increased complete tumor eradication rates, especially in aggressive cancers.
  • CREATE-X and KATHERINE trials demonstrated survival advantages (6.5% and 7%, respectively) by adding targeted therapies in patients whose disease persisted after initial treatment.
  • Neoadjuvant therapy may result in a survival advantage, offering patients greater opportunities for cure and personalized treatment planning.

Chemotherapy has long been central to breast cancer treatment, most often administered after surgery to help reduce the risk of recurrence. In recent years, however, oncologists have increasingly explored the benefits of giving chemotherapy before surgery, an approach called neoadjuvant therapy. Historically, this strategy improved surgical outcomes but did not clearly extend survival. Today, new evidence suggests that this may be changing.

Defining Neoadjuvant Therapy

Neoadjuvant therapy refers to the administration of chemotherapy prior to surgical removal of the cancerous tumor. The goal is to weaken or eliminate cancer cells before an operation takes place. This approach provides important information about how a tumor responds to treatment and can guide the use of additional therapies after surgery.

Historical Role and Surgical Benefits

Traditionally, the value of neoadjuvant therapy was tied to surgical outcomes rather than survival. In patients with a small number of cancerous axillary lymph nodes, for example, preoperative chemotherapy eradicated disease in approximately 25–30% of cases. This spared many women from complete lymph node dissection and lowered the long-term risk of lymphedema.

For women with tumors too large for lumpectomy, shrinking the cancer before surgery made breast-conserving procedures possible. In addition, neoadjuvant therapy often made skin-sparing and nipple-sparing mastectomy safer to perform. Perhaps most importantly, it provided oncologists with insight into whether a tumor was responsive to certain drugs, allowing treatment to be adjusted after surgery.

What it did not consistently provide, until recently, was a measurable improvement in survival. That omission is now being addressed through a series of landmark clinical trials.

Clinical Trials Demonstrating Survival Benefit

Several pivotal studies have reshaped how oncologists view neoadjuvant therapy:

  • KEYNOTE-522 Trial: This study evaluated standard chemotherapy given with pembrolizumab (Keytruda®), an immune checkpoint inhibitor. Patients in the combined therapy group experienced a 14% higher rate of complete cancer disappearance compared with those who received chemotherapy alone.
  • I-SPY2 Trial: Using the same immune therapy approach, researchers reported a 27% improvement in complete tumor eradication. The strongest responses were observed in patients with the most aggressive cancers.
  • CREATE-X Trial (Japan): This trial focused on patients whose cancers persisted despite preoperative chemotherapy. After surgery, participants were randomized to receive capecitabine or no further treatment. Those receiving capecitabine achieved a 6.5% survival advantage, one of the first clear demonstrations of survival improvement in this setting.
  • KATHERINE Trial: In patients with HER2-positive disease, standard biologic therapy was compared with TDM-1 (Kadcyla®), a targeted therapy combining trastuzumab with chemotherapy. Among patients with residual disease, TDM-1 produced a 7% survival advantage.

Taken together, these trials show that neoadjuvant therapy can improve outcomes by shrinking tumors and extending the lives of selected patients.

Implications for Patients

For women facing breast cancer, these findings are both promising and encouraging. The choice to use preoperative chemotherapy depends on tumor type, stage, and individual treatment goals. For some, it allows for breast-conserving surgery or advanced reconstructive techniques. For others, it provides an opportunity for oncologists to intensify therapy if the cancer does not fully respond.

Most importantly, these studies demonstrate that neoadjuvant therapy is no longer limited to surgical preparation. For certain patient groups, it is associated with a meaningful improvement in survival.

Conclusion

Neoadjuvant therapy is emerging as more than a bridge to surgery. It is becoming a pivotal part of modern breast cancer treatment, offering both surgical advantages and measurable survival benefits. With the introduction of immune checkpoint inhibitors and advanced biologic agents such as capecitabine and TDM-1, this approach has the potential to improve cure rates and redefine standards of care. 

For women navigating breast cancer, these developments bring new options, new hope, and greater opportunities for long-term healing.